Also known as Isentress
Raltegravir (RAL, Isentress™, formerly MK-0518) is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.Source: Wikipedia
Estimated Total Cost: $887.68 for an average of 28 days supply
Patients are most commonly prescribed raltegravir to treat human immunodeficiency virus infection (hiv), viral hepatitis, rabies, and blastomycosis.